Li Yang

Lanzhou, 730000, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

PRDX1 as a novel urinary biomarker for bladder cancer: Development of an integrated fiber optic sensing platform.

PRDX1 as a novel urinary biomarker for bladder cancer: Development of an integrated fiber optic sensing platform.

Journal: Talanta
Published: April 17, 2026

Circulating metabolites and bladder cancer: a Mendelian randomization and multi-omics study.

Circulating metabolites and bladder cancer: a Mendelian randomization and multi-omics study.

Journal: Discover oncology
Published: July 04, 2025

TPI1 enhances gemcitabine resistance in bladder cancer by promoting autophagy through activating Beclin-1.

TPI1 enhances gemcitabine resistance in bladder cancer by promoting autophagy through activating Beclin-1.

Journal: Cell death & disease
Published: July 01, 2025

TPI1 promotes p53 ubiquitination in bladder cancer by recruiting AKT to enhance MDM2 phosphorylation.

TPI1 promotes p53 ubiquitination in bladder cancer by recruiting AKT to enhance MDM2 phosphorylation.

Journal: Pharmacological research
Published: January 21, 2025

A machine learning-based prognostic signature utilizing MSC proteomics for predicting bladder cancer prognosis and treatment response.

A machine learning-based prognostic signature utilizing MSC proteomics for predicting bladder cancer prognosis and treatment response.

Journal: Translational oncology
Published: November 04, 2024

BIN1 inhibited tumor growth, metastasis and stemness by ALDH1/NOTCH pathway in bladder carcinoma.

BIN1 inhibited tumor growth, metastasis and stemness by ALDH1/NOTCH pathway in bladder carcinoma.

Journal: Hereditas
Published: September 25, 2024

Mechanistic insights into PROS1 inhibition of bladder cancer progression and angiogenesis via the AKT/GSK3β/β-catenin pathway.

Mechanistic insights into PROS1 inhibition of bladder cancer progression and angiogenesis via the AKT/GSK3β/β-catenin pathway.

Journal: Scientific reports
Published: August 26, 2024

Urine proteomics-based analysis identifies CHI3L1 as an immune marker and potential therapeutic target for bladder cancer.

Urine proteomics-based analysis identifies CHI3L1 as an immune marker and potential therapeutic target for bladder cancer.

Journal: BMC cancer
Published: July 22, 2024

Mesenchymal stem cells in tumor microenvironment: drivers of bladder cancer progression through mitochondrial dynamics and energy production.

Mesenchymal stem cells in tumor microenvironment: drivers of bladder cancer progression through mitochondrial dynamics and energy production.

Journal: Cell death & disease
Published: February 20, 2024

Identification of a Novel Mesenchymal Stem Cell-Related Signature for Predicting the Prognosis and Therapeutic Responses of Bladder Cancer.

Identification of a Novel Mesenchymal Stem Cell-Related Signature for Predicting the Prognosis and Therapeutic Responses of Bladder Cancer.

Journal: Stem cells international
Published: December 20, 2023

Identification of the role of MCM6 in bladder cancer prognosis, immunotherapy response, and in vitro experimental investigation using multi-omics analysis.

Identification of the role of MCM6 in bladder cancer prognosis, immunotherapy response, and in vitro experimental investigation using multi-omics analysis.

Journal: Life sciences
Published: August 17, 2023

Integrated molecular analyses of an interferon-γ based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification.

Integrated molecular analyses of an interferon-γ based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification.

Journal: Heliyon
Published: August 31, 2022
Showing 1-12 of 12

Last Updated: 09/26/2026